In a filing, Amylyx Pharmaceuticals Inc revealed its Chief Financial Officer FRATES JAMES M unloaded Company’s shares for reported $37806.0 on Mar 31 ’25. In the deal valued at $3.47 per share,10,896 shares were sold. As a result of this transaction, FRATES JAMES M now holds 290,988 shares worth roughly $1.55 million.
Then, Bedrosian Camille L sold 12,425 shares, generating $43,082 in total proceeds. Upon selling the shares at $3.47, the Chief Medical Officer now owns 194,375 shares.
Before that, Mazzariello Gina sold 9,192 shares. Amylyx Pharmaceuticals Inc shares valued at $31,954 were divested by the Chief Legal Officer at a price of $3.48 per share. As a result of the transaction, Mazzariello Gina now holds 187,969 shares, worth roughly $1.0 million.
Citigroup initiated its Amylyx Pharmaceuticals Inc [AMLX] rating to a Buy in a research note published on June 17, 2025; the price target was $12. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in late May with a ‘”a Buy”‘ rating. Mizuho also remained covering AMLX and has increased its forecast on April 07, 2025 with a “an Outperform” recommendation from previously “Neutral” rating. Robert W. Baird revised its rating on November 18, 2024. It rated AMLX as “an Outperform” which previously was an “a Neutral”.
Price Performance Review of AMLX
On Tuesday, Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] saw its stock fall -2.02% to $5.33. Over the last five days, the stock has lost -7.47%. Amylyx Pharmaceuticals Inc shares have risen nearly 41.01% since the year began. Nevertheless, the stocks have risen 217.26% over the past one year. While a 52-week high of $7.27 was reached on 06/11/25, a 52-week low of $1.58 was recorded on 03/04/25.
Levels Of Support And Resistance For AMLX Stock
The 24-hour chart illustrates a support level at 5.21, which if violated will result in even more drops to 5.08. On the upside, there is a resistance level at 5.56. A further resistance level may holdings at 5.78.
